Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
ImpediMed Limited has achieved critical reimbursement coverage of its SOZO Digital Health Platform for lymphedema testing in the state of Michigan, with over 80% of the state's insured population having access. This includes Blue Cross Blue Shield of Michigan supporting testing using SOZO.
With the achievement, there's a large available market in Michigan and existing customers include significant health systems such as Ascension Health, Corewell Health, Trinity Health, and the University of Michigan. Authorization is not required for SOZO measurements which simplifies the reimbursement process.
A significant part of ImpediMed's strategy is gaining broad national coverage through large regional Payors, with BCBS Michigan being a pivotal step. The company projects nearly all Private Payors to publish coverage by the end of the fiscal year 2024.
The National Comprehensive Cancer Network (NCCN) has included bioimpedance spectroscopy (BIS) as an objective measurement tool to identify early signs of lymphoedema in its clinical practice guidelines for survivorship.
The NCCN recommends that cancer survivors at risk of lymphoedema undergo regular screening via symptom assessment, clinical exam, and if available, BIS.
ImpediMed has the only FDA-cleared BIS technology for the assessment of lymphoedema, and the inclusion of BIS in the NCCN guidelines will help establish it as a standard of care and accelerate adoption by private payers and providers.